Exelixis, an oncology company based in Alameda, California, focuses on developing treatments for difficult-to-treat cancers, with four marketed products including cabozantinib for various cancers. Founded in 2000, it employs 1,310 people.
Patrick J Haley sold 34,387 shares of EXEL on 20 May at $44.06 per share, worth a total of $1.5M. They now own 412,072 EXEL shares, or a 8% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
